Logo image of RN.MI

RISANAMENTO SPA (RN.MI) Stock Fundamental Analysis

Europe - BIT:RN - IT0001402269 - Common Stock

0.0214 EUR
0 (-0.93%)
Last: 10/21/2025, 7:00:00 PM
Fundamental Rating

1

RN gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 72 industry peers in the Real Estate Management & Development industry. RN may be in some trouble as it scores bad on both profitability and health. RN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

RN had negative earnings in the past year.
RN had a positive operating cash flow in the past year.
In the past 5 years RN reported 4 times negative net income.
In the past 5 years RN reported 4 times negative operating cash flow.
RN.MI Yearly Net Income VS EBIT VS OCF VS FCFRN.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

RN has a worse Return On Assets (-17.00%) than 86.11% of its industry peers.
RN has a worse Return On Equity (-1954.84%) than 87.50% of its industry peers.
Industry RankSector Rank
ROA -17%
ROE -1954.84%
ROIC N/A
ROA(3y)-10.95%
ROA(5y)-7.97%
ROE(3y)-342.17%
ROE(5y)-214.79%
ROIC(3y)N/A
ROIC(5y)N/A
RN.MI Yearly ROA, ROE, ROICRN.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

RN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RN.MI Yearly Profit, Operating, Gross MarginsRN.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

1

2. Health

2.1 Basic Checks

RN does not have a ROIC to compare to the WACC, probably because it is not profitable.
RN has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for RN remains at a similar level compared to 5 years ago.
Compared to 1 year ago, RN has a worse debt to assets ratio.
RN.MI Yearly Shares OutstandingRN.MI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B
RN.MI Yearly Total Debt VS Total AssetsRN.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -0.83, we must say that RN is in the distress zone and has some risk of bankruptcy.
RN has a Altman-Z score of -0.83. This is amonst the worse of the industry: RN underperforms 84.72% of its industry peers.
A Debt/Equity ratio of 1.42 is on the high side and indicates that RN has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.42, RN is doing worse than 72.22% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.42
Debt/FCF N/A
Altman-Z -0.83
ROIC/WACCN/A
WACC7.97%
RN.MI Yearly LT Debt VS Equity VS FCFRN.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 1.47 indicates that RN should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.47, RN is in line with its industry, outperforming 56.94% of the companies in the same industry.
RN has a Quick Ratio of 1.47. This is a bad value and indicates that RN is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of RN (0.59) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.47
Quick Ratio 0.59
RN.MI Yearly Current Assets VS Current LiabilitesRN.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

RN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.00%, which is quite impressive.
The Revenue has grown by 191.49% in the past year. This is a very strong growth!
Measured over the past years, RN shows a very negative growth in Revenue. The Revenue has been decreasing by -59.85% on average per year.
EPS 1Y (TTM)25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.83%
Revenue 1Y (TTM)191.49%
Revenue growth 3Y-39.29%
Revenue growth 5Y-59.85%
Sales Q2Q%93214.29%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RN.MI Yearly Revenue VS EstimatesRN.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RN. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RN.MI Price Earnings VS Forward Price EarningsRN.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RN.MI Per share dataRN.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.01 -0 0.01

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RISANAMENTO SPA

BIT:RN (10/21/2025, 7:00:00 PM)

0.0214

0 (-0.93%)

Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryReal Estate Management & Development
Earnings (Last)07-28 2025-07-28
Earnings (Next)10-30 2025-10-30
Inst Owners48.89%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap38.54M
Revenue(TTM)26.20M
Net Income(TTM)-26273000
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.47
P/FCF N/A
P/OCF 53.38
P/B 28.67
P/tB 29.49
EV/EBITDA N/A
EPS(TTM)-0.01
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0
FCFYN/A
OCF(TTM)0
OCFY1.87%
SpS0.01
BVpS0
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -17%
ROE -1954.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-10.95%
ROA(5y)-7.97%
ROE(3y)-342.17%
ROE(5y)-214.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity 1.42
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 294.74%
Cap/Sales 5.34%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.47
Quick Ratio 0.59
Altman-Z -0.83
F-Score5
WACC7.97%
ROIC/WACCN/A
Cap/Depr(3y)179.32%
Cap/Depr(5y)109.66%
Cap/Sales(3y)364.44%
Cap/Sales(5y)228.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.83%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)191.49%
Revenue growth 3Y-39.29%
Revenue growth 5Y-59.85%
Sales Q2Q%93214.29%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y28.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-100.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-99.22%
OCF growth 3YN/A
OCF growth 5YN/A